Medical Doctor Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Madhur Batra

Pain Medicine Boston, MA Medical Doctor

NPI 1831726314 CMS profile 11420078

55 Fruit St, Boston, MA 02114

Open in the dashboard

General payments

$2,603

75 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Madhur Batra of Boston, MA is reported in the CMS Open Payments database as having received $2,603 across 75 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 58th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,658 15
2024 General $514 29
2023 General $393 28
2022 General $39 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Madhur Batra
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Madhur Batra were reported at $1,658. Among 1,144 Pain Medicine profiles paid that year, the median was $402 and the middle half received between $130 and $1,173.

Show as a table
Year Madhur Batra Pain Medicine median Middle half National median
2019 $0 $409 $115–$1,311 $163
2020 $0 $214 $66–$666 $114
2021 $0 $299 $84–$899 $132
2022 $39 $335 $103–$1,149 $149
2023 $393 $376 $114–$1,228 $160
2024 $514 $387 $115–$1,173 $164
2025 $1,658 $402 $130–$1,173 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Abbott Laboratories $1,130 7 payments
  2. AbbVie, Inc. $795 58 payments
  3. Boston Scientific Corporation $142 1 payment
  4. MML US, Inc. $133 1 payment
  5. Globus Medical, Inc. $113 1 payment
  6. SI-BONE, Inc. $100 1 payment
  7. Medtronic, Inc. $66 2 payments
  8. SPR Therapeutics, Inc $54 1 payment
  9. Merz Pharmaceuticals, LLC $38 1 payment
  10. Ipsen Biopharmaceuticals, Inc $33 2 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $1,614 70 payments
  2. Travel and Lodging $989 5 payments
Products named General payments · program years 2022–2025
  1. PROCLAIM $1,026 6 payments
  2. BOTOX Botox Therapeutic $748 54 payments
  3. General - Pain Management $142 1 payment
  4. ReActiv8 $133 1 payment
  5. Senza $113 1 payment
  6. ETERNA $104 1 payment
  7. QULIPTA $90 4 payments
  8. SPRINT PNS System $54 1 payment
  9. INTELLIS ADAPTIVESTIM $50 1 payment
  10. BOTOX Neuroscience $48 4 payments
  11. Other $120 6 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

200

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$2,297

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

26%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 33 $697
Gabapentin Generic 57 $578
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 19 $327
Oxycodone Hcl Generic 11 $237
Pregabalin Generic 14 $179
Methocarbamol Generic 11 $160
Duloxetine Hcl Generic 16 $72
Tizanidine Hcl Generic 14 $27
Metoprolol Tartrate Generic 11 $14
Diazepam Generic 14 $6

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $313
$313 — —
QULIPTA
  • AbbVie, Inc. $18
$18 — —
UBRELVY
  • AbbVie, Inc. $17
$17 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

75 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record